998 related articles for article (PubMed ID: 26940352)
1. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
2. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
3. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
4. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials.
Kreuter M; Koegler H; Trampisch M; Geier S; Richeldi L
Respir Res; 2019 Apr; 20(1):71. PubMed ID: 30971229
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
[TBL] [Abstract][Full Text] [Related]
6. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
8. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
[TBL] [Abstract][Full Text] [Related]
9. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Nakano A; Ohkubo H; Fukumitsu K; Fukuda S; Kanemitsu Y; Takemura M; Maeno K; Ito Y; Oguri T; Niimi A
Intern Med; 2019 Apr; 58(8):1141-1144. PubMed ID: 30568147
[TBL] [Abstract][Full Text] [Related]
10. Evaluating new treatment options.
Nathan SD
Am J Manag Care; 2017 Jul; 23(11 Suppl):S183-S190. PubMed ID: 28978213
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Mazzei ME; Richeldi L; Collard HR
Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
17. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
18. Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
Kai Y; Matsuda M; Fukuoka A; Hontsu S; Yamauchi M; Yoshikawa M; Muro S
Thorac Cancer; 2021 May; 12(9):1457-1460. PubMed ID: 33742758
[TBL] [Abstract][Full Text] [Related]
19. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
20. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
